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A large number of diverse functions have been
attributed to the BRCA1 and BRCA2 breast cancer
susceptibility genes. Here we review recent progress in
the field.
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Introduction
About one in ten women in the Western world develop
cancer of the breast and at least 5% of these cases are
thought to result from a hereditary predisposition to the
disease [1]. Two breast cancer susceptibility (BRCA) genes
have been mapped and cloned (Figure 1), and mutations
in these genes underlie the disease in most families in
which four or more cases of breast cancer are diagnosed in
women below the age of 60. Women who inherit loss-of-
function mutations in one allele of either of these genes
have an up to 85% risk of breast cancer by age 70. Both
BRCA1 and BRCA2 are thought to be tumour suppressor
genes as the wild-type allele of the gene is lost in tumours
of heterozygous carriers. As well as breast cancer, carriers of
mutations in these genes are at elevated risk of cancer in
the ovary, prostate and pancreas. Surprisingly, despite the
association with inherited predisposition, somatic disease-
causing mutations in BRCA1 and BRCA2 are extremely
rare in sporadic breast cancers. Functions for the BRCA
proteins in a bewildering array of biological processes have
been suggested [2]. But whether dysfunction of all or only
a subset of these processes contributes to cancer initiation
or progression is unknown. Here we discuss recent new
findings on the functions of BRCA1 and BRCA2 which
provide more detail on their potential roles in transcrip-
tional regulation and DNA repair and suggest additional
roles in processes such as polyadenylation of mRNA and
protein degradation.
Fixing DNA 
Both BRCA1 and BRCA2 have been consistently linked to
various processes of the repair of damaged DNA. These
Figure 1
Functional domains in the BRCA1 and BRCA2 proteins. The RING finger
is a protein–protein interaction domain which may have ubiquitin ligase
activity. The BRCT domain is another protein–protein interaction motif
which is found principally in proteins involved in DNA metabolism or
repair. BRCA2 contains nine separate potential RAD51 binding domains
— 8 BRC repeats and a structurally independent carboxy-terminal domain.
Both BRCA1 and BRCA2 contain nuclear localisation sequences (NLS).
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include the repair of double-strand breaks by homologous
recombination and the repair of oxidative damage by tran-
scription-coupled repair [3,4]. Now several new papers
provide further insight into the potentially multi-purpose
role of BRCA proteins in DNA repair.
Mammalian cells repair breaks in double-stranded DNA
by non-homologous end joining or by homologous recom-
bination [5,6] (Figure 2). Substantial evidence is now avail-
able for a role for both BRCA1 and BRCA2 in homologous
recombination. Both BRCA1 and BRCA2 can interact
directly or indirectly with RAD51 [7–10], the eukaryotic
equivalent of bacterial RecA. RAD51 catalyses strand
exchange during homology directed repair of DNA double-
strand breaks by gene conversion. Within BRCA2, the
RAD51 interaction is mediated by a number of repeats of a
specific sequence — the BRC repeat — and an unrelated
domain located at the carboxy terminus (Figure 1) [7,9,10].
BRC repeats may regulate the loading of RAD51 onto DNA
[11]. Taken together with the colocalisation of BRCA1 and
BRCA2 with RAD51 in ionising radiation induced nuclear
foci [10], these observations suggest a role for BRCA1 and
BRCA2 in DNA repair by homologous recombination. Fur-
thermore, mouse and human BRCA1 and BRCA2 mutant
cells suffer from chromosome instability [12–17] and have a
heightened sensitivity to DNA lesions that are repaired by
homologous recombination [14,18–21].
A direct and elegant analysis of the ability of BRCA1 and
BRCA2 mutant cells to repair double-strand breaks created
by endonucleases has been performed by Jasin and col-
leagues [22]. Mouse embryonic stem (ES) cells lacking
BRCA1 are deficient in the repair of double-strand breaks
by homologous recombination [23]. Similarly, ES cells
with disruptions in BRCA2 are compromised for repair of
double-strand breaks by gene conversion [24]. Loss of
BRCA2 appears to result in alternative use of the error-
prone single strand annealing pathway (Andrew Tutt, per-
sonal communication). Use of error-prone pathways
instead of BRCA1 and 2 dependent conservative routes to
repair is likely to create considerable genome instability
and may contribute to loss of tumour suppressor genes and
tumorigenic progression.
Models have been proposed to explain the roles of BRCA1
and BRCA2 in the maintenance of chromosome instability
through functions in DNA replication [4]. Stalled replica-
tion forks caused by a variety of mechanisms such as base
lesions, DNA breaks or strand gaps, are thought to require
homologous recombination to restart replication. If homol-
ogous recombination is dysfunctional then stalled replica-
tion forks may lead to persistent DNA breaks and
ultimately to gross chromosomal rearrangements including
translocations. These are indeed frequently seen in cells
lacking BRCA1 and BRCA2 [12–17]. Such rearrangements
may well provide the raw material for the further genetic
changes required for tumour progression.
BACH variations
A recent paper [25] from David Livingston’s group
describes the isolation of BACH1, a novel putative DNA
helicase which interacts with the BRCT domains of
BRCA1. BACH1 contains substantial sequence similarity
to the catalytic and nucleotide binding domains of known
members of the DEAH helicase family which includes the
Xeroderma Pigmentosum complementing group D (XPD)
protein [26–28]. BACH1 binds to BRCA1 and, as helicases
have been implicated in DNA repair, the authors [25] asked
whether BACH1 has such a function. They expressed a
dominant negative mutant of BACH1 in tissue culture
cells and, by measuring the rate of double-strand break
Figure 2
Double-stranded DNA break repair pathways. Non-homologous end
joining results in the direct rejoining of the broken DNA ends and
generally results in small deletions. The heterodimeric DNA end-binding
protein Ku recruits DNA-PK and then XRCC4 and DNA ligase IV. The
Mre11–Rad50–Nbs1complex is involved in end processing before re-
joining. Homologous recombination requires an end binding protein,
Rad52. Rad51 forms a filament along the DNA which facilitates strand
invasion. The resected 3′ end invades a homologous DNA duplex and
is then extended by DNA polymerase. In this simplified model only one
of the possible recombination products is shown. Modified from [76].
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repair after gamma-irradiation, showed that the dominant
negative helicase could interfere with double-strand break
repair. However, whether wild-type BACH1 is required
for double-strand break repair remains an open question.
Although mutations in BRCA1 and BRCA2 account for a
significant proportion of early onset familial cancers, it is
clear that other BRCA genes exist [29]. To test whether
BACH1 might be a novel BRCA gene, Livingston and col-
leagues [25] surveyed a series of breast cancer families and
early onset breast cancers which were devoid of mutations
in BRCA1 and 2. Two heterozygous missense mutations
were identified in BACH1 in germline DNA of two breast
cancer patients. Both these sequence differences resulted
in amino acid changes (P47A and M299I) in the helicase
domain of BACH1 and were thought unlikely to be
common polymorphisms. And both were discovered in
early onset breast cancer patients, one of whom, the carrier
of the P47A change, had a strong family history of breast
and ovarian cancer. Unfortunately the authors were unable
to confirm segregation of this mutation with breast cancer,
as the appropriate DNAs were not available. Furthermore,
the wild-type allele appeared to be retained in the tumour
genome. 
So how might these changes result in early onset breast
cancer? To address this question, mutant and wild-type ver-
sions of BACH1 were expressed ectopically in U20S cells
[25]. Interestingly, the P47A mutation appeared to lead to
destabilisation of the BACH1 protein. In the absence of
evidence that the other allele of BACH1 is affected in the
tumour carrying the P47A mutation, the authors speculate
that haploinsufficiency could contribute to tumour forma-
tion in early onset breast cancer. However, without defini-
tive genetic evidence it is premature to ascribe a significant
role to BACH1 in familial breast cancer and it remains pos-
sible that the sequence changes are rare polymorphisms.
The Fanconi connection
Fanconi’s anemia is an autosomal recessive disorder char-
acterised by cancer susceptibility, congenital abnormalities
and bone marrow failure [30]. Patients with this disease
develop several types of cancer but are particularly prone
to acute myeloid leukemias and squamous cell carcinomas
of the head and neck. The cells of these patients are char-
acterised by chromosomal instability and enhanced sensi-
tivity to bifunctional alkylating agents that cross-link
DNA. Six different genes, FANC1–6, have been shown to
be mutated in patients with Fanconi’s anemia but little is
known about their function or how their mutation leads to
the disease [30]. Recently, a new Fanconi’s anemia gene,
FANCD2, has been isolated [31]. The demonstration that
the product of FANCD2 interacts with BRCA1 may provide
new insights into both Fanconi’s anemia and breast cancer
susceptibility [32]. FANCD2 becomes modified by the
addition of a single ubiquitin residue in response to DNA
damage [32]; this monoubiquitination is distinct from that
generally observed when proteins are targeted for degrada-
tion (see below). Coincident with the ubiquitin modifica-
tion, FANCD2 becomes localised to nuclear foci which,
after further examination, were also found to contain
BRCA1. Additional support for a functional interaction
comes from observations that BRCA1 and FANCD2 can
be coimmunoprecipitated from gamma-irradiated cells.
The importance of ubiquitination in the localisation of
FANCD2 and the suggestion that BRCA1 has ubiquitin
E3 ligase activity [33–35] suggests an obvious mechanism
by which BRCA1 regulates FANCD2. Intriguingly radial
aberrations typical of Fanconi’s anemia are observed in
both BRCA1 and BRCA2-null cells [14,15]. 
BRCA1 breaks down
Protein degradation is increasingly being recognised as a
key step in the regulation of embryonic development and
cell growth and differentation. Abnormal regulation of
protein degradation is also critical to the pathogenesis of
neurodegenerative diseases and cancer. One of the first
features of the BRCA1 protein to be described was the
RING finger domain (see Figure 1), although at the time
the function of this domain was not clearly understood.
Indeed RING fingers were thought capable of interacting
with DNA. Recently, the RING domain has been impli-
cated in the ubiquitin-mediated proteolytic pathway.
A key cellular pathway for protein degradation is medi-
ated by polyubiquitination of specific lysine residues;
polyubiquitinated substrates are degraded by the 26S
proteosome [36]. The ubiquitin E3 ligase catalyses the
formation of polyubiquitin chains on substrate proteins
via iso-peptide bonds using ubiquitin that has been acti-
vated by enzymes E1 and E2 (Figure 3). Specific ligase
complexes are associated with regulation of specific
cellular processes. For example, the Skp1–Cullin–F box
complex, SCF, and the cyclosome or anaphase promoting
complex, APC, are the two major ubiquitin ligase com-
plexes that regulate ubiquitin-mediated proteolysis
during G1/S and anaphase, respectively [37]. Recently
several RING finger proteins, with otherwise diverse
structures, such as c-CBL, IAP, and MDM2 have been
linked to ubiquitination of important regulatory proteins
[33,38–40]. Now BRCA1 has been suggested to function
in ubiquitination [33–35]. Although the BRCA1 RING
domain alone has low E3 ubiquitin ligase activity, a het-
erodimer of RING finger domains of BRCA1 and BARD1
has considerable activity. BARD1 is a RING domain
protein shown in a two-hybrid screen to interact with
BRCA1 RING domain [41]. Intriguingly BARD1 is also
mutated in breast and ovarian tumours, albeit infre-
quently [42]. Although these results are highly sugges-
tive, we still await the finding of physiological targets of
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BRCA1–BARD1 ubiquitination; one potential target, the
FANCD2 protein, was discussed above.
The end in sight?
An intriguing addition to the list of putative functions for
the BRCA1 protein has been a possible role in mRNA pro-
cessing. Kleiman and Manley [43] have shown that
BARD1 interacts with the polyadenylation factor CstF and
inhibits 3′ end processing of mRNA precursors. A more
recent study by the same group [44] showed that DNA
damage by either UV or hydroxyurea could inhibit
polyadenylation in vitro and that this inhibition was medi-
ated via the BARD1–CstF interaction. Regulation of
polyadenylation is thought to play an important role in cell
growth control [45,46]. A complex containing BRCA1,
BARD1 and CstF increases transiently following DNA
damage and inhibits polyadenylation. This may prevent
inappropriate RNA processing and production of aberrant
transcripts. Both BRCA1 and BARD1 can associate with
the RNA polymerase II complex [47,48] which is neces-
sary for efficient 3′ cleavage of mRNA; Kleiman and
Manley [43] propose a model whereby BRCA1 and/or
BARD1, via their RING domain, control degradation of
RNA polymerase II by ubiquitination. A role for BRCA1
in polyadenylation is a previously unsuspected one.
BRCA1–BARD1 may be recruited to sites of stalled tran-
scription as part of a transcription-coupled DNA repair
process [3]. Absence of a functional BRCA1–BARD1
complex might cause dysregulation of gene expression and
perhaps contribute to tumour progression.
Chipping away at BRCA function
The simultaneous analysis of the expression of thousands
of genes by microarrays has started to contribute to our
understanding of how mutations in BRCA1 and BRCA2
can lead to tumour susceptibility and loss of cell growth
control. Using this technology, Harkin et al. [49] showed
that induction of BRCA1 expression can lead to changes
in expression of various genes implicated in growth
control such as GADD45 and EGR1. This led to the iden-
tification of a specific pathway — the JNK/SAPK pathway
— activated during BRCA1-induced apoptosis. Similarly
MacLachlan et al. [50] identified a number of genes whose
transcription was differentially affected by expression of
BRCA1. Some of these genes are obviously involved in
the control of cellular proliferation (Cyclin B1, PIN1,
PCNA) whereas others have been implicated in responding
to DNA damage (GADD45, GADD153). However, it should
be noted that both of these studies were based on BRCA1
overexpression in a BRCA1 wild-type cellular background;
whether this is physiologically relevant to the situation in a
BRCA1 null tumour is not clear.
cDNA microarrays have also been used to show that differ-
ent groups of genes are expressed by tumours arising in
patients carrying mutations in either BRCA1 or BRCA2 [51].
The authors could quite accurately predict from which
genetic mutation different tumours had arisen by the expres-
sion profiles of relatively small groups of genes. A set of 9
genes could be used to distinguish tumours that did or did
not carry BRCA1 mutations and a set of 11 genes could be
used to distinguish tumours that carried BRCA2 mutations,
though to a less statistically significant extent. Follow-up
immunohistochemical analysis using tissue arrays con-
firmed at the protein level that cyclin D1 was more highly
expressed in BRCA2 tumours than in BRCA1 tumours [51].
The above study demonstrates how cDNA and tissue
arrays will be important tools in not just the research labo-
ratory but also in a clinical setting, both diagnostically and
therapeutically. However, it also raises some questions
about the experimental design of microarray experiments
[52]. Gene expression microarray experiments generate
vast quantities of data and there can be tremendous varia-
tion within these data sets, especially when comparing
samples such as panels of tumours. The scientific commu-
nity is still determining the best ways to analyse such large
data sets and is improving algorithms for clustering co-
varying sets of genes. Therefore, as much variation as pos-
sible, particularly in pathological features, needs to be
removed from the samples being compared. Obviously,
this is not always possible and so larger patient or sample
numbers will be needed to validate the changes seen in
the experiments of Hedenfalk et al. [51]. However, it is
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Figure 3
BRCA1–BARD1 heterodimer might function
as an E3 ubiquitin ligase. Free ubiquitin is
activated in an ATP-dependent manner to
form a covalent link with subunit E1. Ubiquitin
is then transferred to one of a number of E2
subunits. E2 then associates with E3 ligases,
such as the BRCA1–BARD1 heterodimer,
which may or may not have substrates already
bound. Ubiquitin is then transferred onto lysine
residues of the substrate. Modified from [77].
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clear that microarray technology should lead to profound
insights into the functions of BRCA1 and BRCA2.
Promiscuous partner in transcription
The analysis of global gene expression changes using
microarrays has added to the already considerable litera-
ture on the role of BRCA1 and BRCA2 in the regulation of
transcription [53]. BRCA1 and BRCA2 regulate transcrip-
tion in concert with a number of cofactors including the
histone acetylases, deacetylases and associated proteins
HDAC, CBP/p300, CtIP and P/CAF, as well as RNA poly-
merase II holoenzyme [53]. Recently, BRCA1 was shown
to interact directly with a novel sequence-specific DNA
binding protein, ZBRK1 [54]. GADD45, a gene which has
been shown to be a target of BRCA1 transcriptional
control in microarray experiments [49,50], is repressed by
ZBRK1. Underscoring the significance of the interaction,
breast cancer-derived BRCA1 mutations that disrupt the
interaction between BRCA1 and ZBRK1 also block the
corepressor activity of the complex [54].
Paradoxically however, BRCA1 overexpression caused an
induction of GADD45 in previous studies. So how does this
tally with a role for BRCA1 as a corepressor of GADD45?
The authors [54] suggest a model whereby BRCA1 and
ZBRK1 repress GADD45 transcription in the uninduced
state, but following a signal such as DNA damage leading
to increased BRCA1 phosphorylation or protein levels,
there is derepression of GADD45 gene transcription. Intrigu-
ingly, this suggests that BRCA1 might play a role in both
corepression and coactivation of the same gene; it will be
interesting to determine which other genes fall under this
putative dual transcription activity. Other genes encoding
potential ZBRK1 binding motifs have been identified [54],
including GADD153, Ki-67, Bax and p21, all of which may
be targets of BRCA1 transcriptional control. 
Another interaction that supports a role for BRCA1 in tran-
scriptional regulation is that with the signal transduction
and activator of transcription protein, STAT1 [55]. BRCA1
binds to the STAT1a transcriptional activation domain
which leads to the induction of a family of interferon-
gamma regulated genes. More recently it has been reported
that over-expression of BRCA1 in prostate cancer cells can
cause activation of not only STAT3 but also the upstream
activators of STAT3, JAK1 and JAK2 [56]. Interestingly,
groups of interferon-induced genes have been shown by a
microarray approach to undergo substantial co-variation in
expression across a panel of breast tumours [57,58]. Inter-
ferons are important regulators of cell growth and apopto-
sis and therefore this role of BRCA1 could be important in
tumour progression.
Tumours arising in BRCA1 mutation carriers are fre-
quently negative for the estrogen receptor. Intriguingly,
it has been reported that BRCA1 can inhibit estrogen
receptor signalling. Overexpression of BRCA1 blocks
estrogen receptor-α mediated activation of an estrogen-
responsive reporter and inhibits the transcriptional activity
of the carboxy-terminal domain of estrogen receptor-α
[59]. Possibly this is mediated by direct interaction of the
receptor and BRCA1 [60]. Others have suggested that
the androgen receptor is transcriptionally coactivated by
BRCA1 and also physically interacts with it [61,62]. It
is not clear yet how BRCA1 might inhibit signalling as
part of an estrogen receptor-α or androgen receptor tran-
scriptional cascade. And the promiscuity of interactions
involving BRCA1 may raise questions about specificity.
However the suggestion of a role for BRCA1 in steroid
hormone signalling is seductive as it may help to explain
the tissue-specific nature of the tumours caused by
BRCA1 mutation.
BRCA1 branches out
Another surprising development has been the demonstra-
tion that BRCA1 can bind directly to DNA with high
affinity but in a sequence non-specific fashion [63]. Recom-
binant BRCA1 binds DNA as a multimer and in doing so
generates DNA loops. BRCA1 has higher affinity for
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Figure 4
(a–f) Electron micrographs of BRCA1 bound to linear plasmid DNA at
the base of DNA loops. From [63].
branched DNA than linear molecules (Figure 4). As a
result of this DNA binding, BRCA1 inhibits the exonu-
clease activity of the Mre11–Rad50–Nbs1 complex that
has been implicated in double-stranded break repair
processes, particularly that of non-homologous end joining
[64]. As mentioned above, BRCA1 deficient mouse cells
exhibit a decrease in the repair of double-stranded DNA
breaks by homologous recombination and an increase in
non-homologous end joining [23]. Paull et al. [63] specu-
late that the inhibition of the exonuclease activity of the
Mre11–Rad50–Nbs1 complex normally provided via
BRCA1 DNA binding might explain the increase in non-
homologous end joining seen in Brca1 deficient cells.
Parvin has suggested a model [65] (Figure 5) incorporating
the new data on DNA binding by BRCA1 with previous
results suggesting a role for the protein in transcription-
coupled repair [3]. According to this model BRCA1 is asso-
ciated with the RNA polymerase II holoenzyme which
becomes arrested at sites of DNA damage. He proposes
that this results in the ubiquitination and degradation of
RNA polymerase II by the BRCA1–BARD1 ubiquitin
ligase heterodimer. This then might lead to dissociation
of the complex leaving BRCA1 bound to the site of the
lesion. BRCA1 would then recruit other factors, such as the
Mre11–Rad50–Nbs1 complex or RAD51, to repair the DNA
damage. Although this model accounts for some observa-
tions, it awaits compelling experimental support.
Complex city
Much of what we know about BRCA1 and BRCA2 has
been derived from descriptions of the various multipro-
tein complexes in which the proteins are found. One of
the first complexes with which BRCA1 was found to be
associated was the RNA polymerase II holoenzyme, a
multi-subunit complex of over 1 MDa [48]. In addition,
BRCA1 has been shown to associate directly with the
Mre11–Rad50–Nbs1 complex [66] which is responsible for
end-processing of double-strand breaks during DNA repair
[64]. More recently BRCA1 has been shown to be associ-
ated with other large complexes involved in DNA repair or
chromatin remodelling. 
The BRCA1 associated genome surveillance complex,
BASC [67], is larger than 2 MDa and contains at least 15
subunits. As well as BRCA1, the complex contains the
products of the Bloom’s syndrome and ataxia telangiecta-
sia (ATM) disease genes. Four subcomplexes implicated
in DNA repair — Mre11–Rad50–Nbs1, the MSH2–MSH6
heterodimer, the MLH1–PMS2 heterodimer and DNA
replication factor C — are present in BASC. The presence
of mismatch repair proteins in BASC provides support for
the suggestion that BRCA1 is important for transcription
coupled repair of oxidation-induced DNA damage [3]. Alter-
natively, mismatch repair proteins have been shown to have
a role in homology searching during double-strand break
repair [68] and this may also explain their presence in BASC.
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Figure 5
Model of the role of BRCA1 in transcription-
coupled repair. An RNA polymerase II
holoenzyme–BRCA1–BARD1 transcription
complex reaches damaged DNA, depicted as
a flap, where it arrests. At this point the
BRCA1–BARD1–E3 ubiquitin ligase complex
becomes active leading to the ubiquitination of
RNA polymerase II and its degradation.
BRCA1 remains bound to the DNA where it
recruits a complex which repairs the lesion.
Modified from [65].
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Many of the DNA repair proteins in BASC can bind abnor-
mal DNA structures such as double-strand breaks, Holli-
day junctions and cruciform DNA. Hence the complex may
act as a DNA structure surveillance unit consisting of both
DNA damage sensors and proteins such as ATM and the
related cell cycle checkpoint kinase, ATR, which could
signal DNA damage. ATM and ATR can directly phospho-
rylate BRCA1 in response to DNA damage and this is
thought to be important for the function of BRCA1 in
double-stranded break repair and cell cycle checkpoint
control [69–71]. As many of the proteins in BASC are
involved in repairing DNA damage that can occur at repli-
cation forks, BRCA1, by association, may also participate
in the resolution of inappropriate DNA structures during
post-replicational repair.
As well as being associated with BASC and the RNA poly-
merase II holoenzyme, BRCA1 is also a member of a large
SWI/SNF-related complex which has chromatin remodel-
ling properties [72]. In particular a direct interaction was
demonstrated between BRCA1 and the bromo-domain
containing protein BRG1. Additionally, this provides a link
between BRCA1 and cell cycle progression as BRG1 has
been shown to interact with the critical cell cycle regulator
RB [73]. How does this tally with putative functions for
the BRCA1 protein? Does BRCA1 regulate transcription
via modulation of chromatin structure or is its function in
such a complex to allow access for the DNA repair
machinery? Interestingly, the BRCA1–chromatin remodel-
ling complex does not contain the Mre11–Rad50–Nbs1
complex, other identified BASC components or RNA poly-
merase II. Perhaps the methods of purification are critical
here. BASC was purified by immunoprecipitation from
unfractionated HeLa nuclear extracts [67]. The SWI/SNF
complex on the other hand was affinity purified following
nuclear extract fraction by column chromatography [72].
Association with the RNA polymerase II holoenzyme was
shown by antibody probing of RNA polymerase II-con-
taining fractions from whole cell extracts which had under-
gone column chromatography [48]. These protocols each
yielded different complexes consisting of non-overlapping
sets of subunits, all containing BRCA1; it seems possible
that the different complexes may be present in the cell
simultaneously.
Complexes containing BRCA2 have been less forthcoming
but recently BRCA2 was also shown to be a member of a
large, 2 MDa complex [74]. One of the components of this
complex is BRCA2-associated factor 35kDa, or BRAF35.
BRAF35 was identified as a structural, non-specific, DNA
binding protein, an activity conferred by the high mobility
group — HMG — domain of the protein. Direct interac-
tion of BRCA2 and BRAF35 was demonstrated in vitro and
both proteins share very similar patterns of expression
during embryogenesis with the highest levels in rapidly
dividing cells. Immunoflourescent staining of HeLa cells
with antibodies to BRAF35 localised the protein to mitotic
chromosomes during early chromosome condensation. At
the onset of the metaphase to anaphase transition, this
localisation is lost. BRCA2 is colocalised with these mitotic
chromosomes suggesting a role in cell cycle progression;
indeed microinjection of antibodies to BRAF35 or BRCA2
into synchronised HeLa cells delayed entry into mitosis.
One feature of the HMG domain is an affinity for DNA
with sharp bends [75], this prompted the authors [74] to
look at the DNA binding activity of BRAF35. Gel-shift
assays showed that BRAF35 bound specifically to cruci-
form, or four-way junction, DNA. Such unusual DNA struc-
tures are created during recombination-mediated repair and
after DNA adduct formation; it may be that BRAF35 serves
to target BRCA2 to sites of DNA damage. 
Summary and conclusions
So what are we to make of these findings of disparate and
apparently unrelated functions for BRCA proteins? Well
perhaps for BRCA1 part of the solution lies in the ubiquiti-
nation function of the BRCA1 and BARD1 heterodimer.
Similar models, in which the ubiquitin ligase activity is a key
feature, have been put forward for the role of BRCA1 in
both polyadenylation [44] and DNA repair [64]. One could
imagine scenarios where other roles of BRCA1, for example
in transcriptional regulation, could be partly ascribed to this
enzymatic activity. Perhaps the presence of BRCA1 in a
large number of protein complexes indicates that it has a
generalised role regulating the abundance of individual pro-
teins or the stoichiometry of complexes. This might explain
the rather pleiotropic cellular consequences of loss of the
gene. Given the flurry of activity in the field it seems very
likely that even more new functions for BRCA1 and BRCA2
proteins will be forthcoming over the next few years. We
already have several plausible explanations of how loss of
these genes leads to tumorigenesis but whether these actu-
ally operate in a woman carrying a BRCA mutation is still
unclear. The key question of why tumours arising through
BRCA mutations are relatively specific to the breast and
ovary is also unresolved. 
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